Della Pasqua News Today : Breaking News, Live Updates & Top Stories | Vimarsana

How can we ensure that diversity, equity, inclusion, and access are truly achieved in clinical trials industry-wide?

ng Therapeutics (GRADIENT), with a combined funding commitment of GBP 2.8 million (USD 3.6 million) over five years, calls on African researchers to submit robust research proposals on the relevance of African genetic diversity to the treatment of malaria and tuberculosis (TB). 1 Lutz Hegemann, M.D., Chief Operating Officer for Global Health at Novartis said: “Novartis has a long-standing commitment to improving and extending the lives of patients around the world.  Our efforts include seeking innovative ways to improve the standard of care where possible. This is why we are excited by t...

ng Therapeutics (GRADIENT), with a combined funding commitment of GBP 2.8m (USD 3.6 million) over five years, calls on African researchers to submit robust research proposals on the relevance of African genetic diversity to the treatment of malaria and tuberculosis. 1 Pauline Williams, Senior Vice President Global Health Pharma at GSK said: “At GSK, human genetics is a core pillar of our R&D strategy. Genetic diversity is greater in Africa than in any other continental population resulting in some African patients having varying response to treatments. We are excited to launch Project Afr...